Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis

Li, D., Pain, O., Fabbri, C., Wong, W., Lo, C., Ripke, S., Cattaneo, A., Souery, D., Dernovsek, M., Henigsberg, N., Hauser, A., Lewis, G., Mors, O., Perroud, N., Rietschel, M., Uher, R., Maier, W., Baune, B., Biernacka, J., Bondolfi, G., Domschke, K., Kato, M., Liu, Y., Serretti, A., Tsai, S., Weinshilboum, R., Major Depressive Disorder Working Group, Psychiatric Genomics Consortium and Jones, Lisa ORCID: https://orcid.org/0000-0002-5122-8334 (2024) Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis. Translational Psychiatry, 14 (296). pp. 1-8. ISSN 2158-3188

	Text (Depositor Upload) Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation a meta-analysis.pdf - Published Version Restricted to Repository staff only Download (962kB) | Request a copy
	Text (Depositor Upload) Supplementary materials.pdf - Supplemental Material Restricted to Repository staff only Download (3MB) | Request a copy
Preview	Text Binder1.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview
Preview	Text Binder5.pdf - Supplemental Material Available under License Creative Commons Attribution. Download (3MB) | Preview

Abstract

Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13 studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to metabolic phenotypes (poor, intermediate, normal, and rapid+ultrarapid) of CYP2C19 and CYP2D6. CYP2D6 structural variants cannot be imputed from genotype data, limiting the determination of metabolic phenotypes, and precluding testing for association with response. The association of CYP2C19 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033, heterogeneity I2 = 0%, subgroup difference p = 0.72). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European- and East Asian-ancestry studies. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. Sequencing and targeted pharmacogenetic testing, alongside information on side effects, antidepressant dosage, depression measures, and diverse ancestry studies, would more fully capture the influence of metabolic phenotypes.

Actions (login required)

View Item